CL2023001530A1 - Derivados espiráncos sustituidos de cadena lineal - Google Patents

Derivados espiráncos sustituidos de cadena lineal

Info

Publication number
CL2023001530A1
CL2023001530A1 CL2023001530A CL2023001530A CL2023001530A1 CL 2023001530 A1 CL2023001530 A1 CL 2023001530A1 CL 2023001530 A CL2023001530 A CL 2023001530A CL 2023001530 A CL2023001530 A CL 2023001530A CL 2023001530 A1 CL2023001530 A1 CL 2023001530A1
Authority
CL
Chile
Prior art keywords
derivatives
linear chain
chain substituted
substituted spiral
spiral
Prior art date
Application number
CL2023001530A
Other languages
English (en)
Inventor
Cai Wei
Dai Xuedong
Alexis Georges Querolle Olivier
Wilhelmus John F Thuring Johannes
Liu Yingtao
Liu Lianzhu
Xu Yanping
Li Ming
Fang Lichao
Deng Xiangjun
Fu Liqiang
Zhao Qiwu
Li Kangying
Tee Fuay Ng Alicia
Freddy J Darville Nicolas
Cleator Edward
Thomas Urbanietz Gregor
Marc Maton William
Pande Vineet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2023001530A1 publication Critical patent/CL2023001530A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, a una composición farmacéutica que comprende tales compuestos y a su uso como inhibidores de la interacción proteína/proteína de la menina/MLL, útiles para tratar enfermedades tales como el cáncer, que incluye, sin carácter limitante, leucemia, síndrome mielodisplásico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
CL2023001530A 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal CL2023001530A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04

Publications (1)

Publication Number Publication Date
CL2023001530A1 true CL2023001530A1 (es) 2023-11-03

Family

ID=76476870

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2022001583A CL2022001583A1 (es) 2019-12-19 2022-06-13 Derivados espiráncos sustituidos de cadena lineal
CL2023001530A CL2023001530A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal
CL2023001531A CL2023001531A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022001583A CL2022001583A1 (es) 2019-12-19 2022-06-13 Derivados espiráncos sustituidos de cadena lineal

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023001531A CL2023001531A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal

Country Status (19)

Country Link
US (1) US20230142285A1 (es)
EP (1) EP4077312A4 (es)
JP (1) JP2023506530A (es)
KR (1) KR20220118500A (es)
CN (4) CN118255773A (es)
AU (1) AU2020404305A1 (es)
CA (1) CA3161045A1 (es)
CL (3) CL2022001583A1 (es)
CO (1) CO2022009085A2 (es)
CR (1) CR20220346A (es)
DO (1) DOP2022000125A (es)
EC (1) ECSP22054700A (es)
IL (1) IL293965A (es)
JO (1) JOP20220154A1 (es)
MX (1) MX2022007652A (es)
PE (1) PE20230162A1 (es)
TW (1) TW202138367A (es)
UY (1) UY38988A (es)
WO (1) WO2021121327A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220119094A (ko) 2019-12-19 2022-08-26 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
CA3214746A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
AU2022271993A1 (en) 2021-05-11 2024-01-04 Janssen Pharmaceutica Nv Combination therapies
IL308335A (en) 2021-05-11 2024-01-01 Janssen Pharmaceutica Nv Combined treatments
AU2022286467A1 (en) 2021-06-01 2024-01-25 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES
CN117425659A (zh) 2021-06-03 2024-01-19 詹森药业有限公司 哒嗪或被螺环胺取代的1,2,4-三嗪
IL309359A (en) * 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexane-3-yl)- salt 6,2-diazaspiro[4.3]octan-6-yl)-4,2,1-triazin-6-yl)oxy) benzamide besylate for the treatment of diseases such as cancer
EP4271676A1 (en) * 2021-12-03 2023-11-08 Bionova Pharmaceuticals (Shanghai) Limited Carbonyl substituted diazaspiro compounds and its use
TW202415660A (zh) * 2022-09-02 2024-04-16 大陸商和記黃埔醫藥（上海）有限公司 三嗪類化合物及其用途
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) * 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
US10053477B2 (en) * 2014-07-04 2018-08-21 Qilu Pharmaceutical Co., Ltd. Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
CN105330698B (zh) * 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
US20170275302A1 (en) * 2014-10-14 2017-09-28 Alexander Pasternak Inhibitors of the renal outer medullary potassium channel
KR20180103053A (ko) * 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 메닌-mll 상호작용의 억제제
LT3468966T (lt) * 2016-06-10 2021-02-25 Vitae Pharmaceuticals, Llc Menino-mll sąveikos inhibitoriai
DK3512857T3 (da) * 2016-09-14 2021-05-10 Janssen Pharmaceutica Nv Spiro-bicykliske inhibitorer af menin-mll-interaktion
FI3512850T3 (fi) * 2016-09-16 2023-06-20 Vitae Pharmaceuticals Llc Meniini-mll-interaktion estäjiä
US11944627B2 (en) * 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
WO2018226976A1 (en) * 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US11649251B2 (en) * 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置

Also Published As

Publication number Publication date
AU2020404305A1 (en) 2022-08-04
CR20220346A (es) 2022-10-26
CN118255774A (zh) 2024-06-28
CO2022009085A2 (es) 2022-07-08
CL2022001583A1 (es) 2023-02-03
EP4077312A4 (en) 2024-01-17
WO2021121327A1 (en) 2021-06-24
MX2022007652A (es) 2022-09-23
CL2023001531A1 (es) 2023-11-03
DOP2022000125A (es) 2022-08-31
US20230142285A1 (en) 2023-05-11
EP4077312A1 (en) 2022-10-26
JOP20220154A1 (ar) 2023-01-30
KR20220118500A (ko) 2022-08-25
CN118255773A (zh) 2024-06-28
ECSP22054700A (es) 2022-11-30
IL293965A (en) 2022-08-01
UY38988A (es) 2021-06-30
JP2023506530A (ja) 2023-02-16
CN118344372A (zh) 2024-07-16
TW202138367A (zh) 2021-10-16
CN114867721A (zh) 2022-08-05
CA3161045A1 (en) 2021-06-24
PE20230162A1 (es) 2023-02-01

Similar Documents

Publication Publication Date Title
CL2023001530A1 (es) Derivados espiráncos sustituidos de cadena lineal
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
ECSP23095641A (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
UY35293A (es) Isotiazoles sustituidos con amino
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
BR112016002311A2 (pt) combinações de inibidor de cinase de pim
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
MX2023013176A (es) Derivados espiro sustituidos.
MX2023013174A (es) Derivados espiro sustituidos.
CL2016000024A1 (es) Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
CO2023018577A2 (es) Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
CL2011000647A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de enlace de la proteina smac al iap; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades proliferativas. (divisional de la solicitud 2234-2007).
CL2011000645A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; y composicion farmaceutica que los comprende; y su uso en eltratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).
CL2011000646A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; composicion farmaceutica que los comprende; util en el tratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).